Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib
Drug: Entrectinib
Drug: Atezolizumab
Drug: Divarasib
Drug: Cisplatin
Drug: Pemetrexed
Drug: Docetaxel
Drug: Cobimetinib
Drug: Gemcitabine
Drug: Carboplatin
Drug: Vemurafenib
Drug: Bevacizumab

First Posted Date: 2017-06-07

Last Posted Date: 2024-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03178552

Locations: 🇺🇸
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States

and more 174 locations

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Guadecitabine

First Posted Date: 2017-06-07

Last Posted Date: 2021-11-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT03179943

Locations: 🇺🇸
USC Norris Hospital and Clinics, Los Angeles, California, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2

Active, not recruiting

Conditions: Metastatic Melanoma
Refractory Melanoma
BRAF V600 Wild Type
Metastatic Malignant Neoplasm in the Brain
Clinical Stage IV Cutaneous Melanoma AJCC v8
Intracranial Melanoma
Pathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions: Drug: Atezolizumab
Biological: Bevacizumab
Procedure: Quality-of-Life Assessment
Drug: Cobimetinib

First Posted Date: 2017-06-05

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03175432

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1

Active, not recruiting

Conditions: Gliosarcoma
Glioblastoma

Interventions: Drug: Atezolizumab
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2017-06-02

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT03174197

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Endometrial Cancer
Gastric Cancer
Renal Cell Carcinoma
Castration-resistant Prostate Cancer
Colorectal Cancer
Differentiated Thyroid Cancer
Ovarian Cancer
Lower Esophageal Cancer
Urothelial Carcinoma

Interventions: Drug: atezolizumab
Drug: cabozantinib

First Posted Date: 2017-05-31

Last Posted Date: 2023-07-27

Lead Sponsor: Exelixis

Target Recruit Count: 1732

Registration Number: NCT03170960

Locations: 🇺🇸
Exelixis Clinical Site #51, Newport Beach, California, United States
🇪🇸
Exelixis Clinical Site #94, Oviedo, Asturias, Spain
🇺🇸
Exelixis Clinical Site #10, Boston, Massachusetts, United States

and more 121 locations

Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer

Phase 2

Completed

Conditions: Cancer, Breast
Triple Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Cyclophosphamide
Drug: Pegylated liposomal doxorubicin
Other: Placebo

First Posted Date: 2017-05-24

Last Posted Date: 2024-10-14

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 68

Registration Number: NCT03164993

Locations: 🇩🇰
Vejle Sygehus, Vejle, Denmark
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇳🇴
Oslo University Hospital, Oslo, Norway

and more 2 locations

NCT Neuro Master Match - N²M² (NOA-20)

Phase 1

Completed

Conditions: Glioblastoma, Adult

Interventions: Drug: Temsirolimus
Drug: APG101
Drug: Alectinib
Drug: Atezolizumab
Drug: Idasanutlin
Drug: Vismodegib
Drug: Palbociclib

First Posted Date: 2017-05-18

Last Posted Date: 2023-09-28

Lead Sponsor: University Hospital Heidelberg

Target Recruit Count: 228

Registration Number: NCT03158389

Locations: 🇩🇪
University Hospital Mainz, Neurosurgery, Mainz, Germany
🇩🇪
University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
🇩🇪
University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany

and more 10 locations

A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: BL-8040
Drug: Atezolizumab

First Posted Date: 2017-05-16

Last Posted Date: 2020-05-18

Lead Sponsor: BioLineRx, Ltd.

Target Recruit Count: 1

Registration Number: NCT03154827

Locations: 🇺🇸
Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States
🇺🇸
The University of Texas - Md Anderson Cancer Center - Leukemia Center, Houston, Texas, United States
🇨🇿
Fakultni Nemocnice Brno / University Hospital Brno Interni Hematologicka A Onkologicka Klinika / Internal Hematology and Oncology Clinic, Brno, Czechia

and more 9 locations

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3

Active, not recruiting

Conditions: Cancer

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2017-05-11

Last Posted Date: 2024-11-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 382

Registration Number: NCT03148418

Locations: 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸
Angeles Clinic & Rsch Inst, Los Angeles, California, United States
🇺🇸
Northwestern University; Robert H. Lurie Comp Can Ctr, Chicago, Illinois, United States

and more 170 locations

AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Atezolizumab

First Posted Date: 2017-05-10

Last Posted Date: 2022-07-19

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 23

Registration Number: NCT03147040

Locations: 🇳🇱
Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands
🇳🇱
Maastricht University Medical Center, Maastricht, Netherlands

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy